Faeth Therapeutics
Austin, Texas, United States · Biotechnology, Health Care, Medical
Rather the company is aiming to interrogate how nutrition can become a “fifth pillar” of cancer care through scientific study. The company also has another trial aimed at metastatic colorectal cancer.
Key facts
- Headquarters
- Austin, Texas, United States
- Employees
- 27
- Industries
- Biotechnology, Health Care, Medical
- Status
- Public (FTH)
- Website
- faeththerapeutics.com
- Company page
Recent activity at Faeth Therapeutics
- : Faeth Therapeutics Appoints Adam Schayowitz as Class III Director
- : Sensei Biotherapeutics acquires Faeth for PIKTOR program
- : Sensei Biotherapeutics secures $200 million in a concurrent Private Placement while acquiring Faeth Therapeutics to advance its cancer pipeline.
- : Sensei Biotherapeutics acquires Faeth Therapeutics
- : Faeth Therapeutics
- : Faeth Therapeutics raised $25 million in a funding round led by S2G Ventures, bringing total funding to $92 million to advance its PIKTOR phase 2 trial for endometrial cancer.
- : Faeth Therapeutics Appoints Dr. Stephen Hahn as Chief Medical Executive and Dr. Jayson Dallas as Chief Executive Officer
- : Sensei Biotherapeutics Appoints Stephanie Krebs, MS, MBA, as Chief Business Officer
- : Faeth Therapeutics Appoints Debbie Chirnomas, M.D., M.P.H., as Chief Medical Officer - Benzinga
- : Faeth Therapeutics Raises $47 Million To Advance Clinical Trials And Feed The Fight Against Cancer
Faeth Therapeutics funding history
| Date | Round | Amount |
|---|---|---|
| Feb 2026 | Post-IPO Equity | $200.0M |
| Jan 2026 | Venture | $24.4M |
| Oct 2025 | Funding Round | $25.0M |
| Jun 2022 | Funding Round | $47.0M |
| Jan 2022 | Seed | $20.0M |
Leadership
- Adam Schayowitz, Ph.D., Director
- Jayson Dallas, Chief Executive Officer
- Stephanie Krebs, Chief Business Officer
- Debbie Chirnomas, Chief Medical Officer
- Alice Drumheller, Research Staff
Verified email and direct lines for Faeth Therapeutics’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Faeth Therapeutics files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Faeth Therapeutics in the news
- Faeth Presents Updated Preclinical Data at ESMO, including First-Ever Head-to-Head Characterization of PIKTOR against Gedatolisib - Business Wire (Oct 23, 2026)
- Faeth Therapeutics - Crunchbase (Jul 10, 2021)
- Faeth Therapeutics to Participate in Upcoming September Investor Conferences - Business Wire (Sep 01, 2026)
- Faeth Therapeutics raises $47 million to advance clinical trials and feed the fight against cancer - PR Newswire (Jun 30, 2022)
- Sensei Biotherapeutics Announces Name Change to Faeth Therapeutics, Focused on Advancing PIKTOR, an Oral Therapy Targeting One of the Most Frequently Altered Pathways in Cancer - Business Wire (Jun 15, 2026)
- Faeth Therapeutics Strengthens Executive Team with Senior Leadership Appointments - Business Wire (Aug 14, 2026)
- Faeth Therapeutics Appoints Karen Vousden, Ph.D., to Board of Directors - Business Wire (Sep 17, 2026)
- Faeth Therapeutics Announces FDA Grant of Fast Track Designation for PIKTOR Plus Paclitaxel in Biomarker-Selected Advanced Endometrial Cancer - Business Wire (Aug 17, 2026)
Companies similar to Faeth Therapeutics
- Aptose Biosciences · Biotechnology, Health Care, Medical, research, Therapeutics
- Swarm Oncology Ltd · Biotechnology, Health Care, Medical, research, Therapeutics
- Onward Therapeutics SA · Biotechnology, Health Care, Medical, research, Therapeutics
- Celldex · Biotechnology, Health Care, Medical, research, Therapeutics
- Genentech · Biotechnology, Health Care, Medical, research, Therapeutics
About Faeth Therapeutics: questions and answers
What does Faeth Therapeutics do?
Rather the company is aiming to interrogate how nutrition can become a “fifth pillar” of cancer care through scientific study. The company also has another trial aimed at metastatic colorectal cancer.
Where is Faeth Therapeutics headquartered?
Faeth Therapeutics is headquartered in Austin, Texas, United States.
How many employees does Faeth Therapeutics have?
Faeth Therapeutics has about 27 employees.
Has Faeth Therapeutics raised funding?
Yes. Fundz has recorded 5 funding events for Faeth Therapeutics. The most recent, Post-IPO Equity of $200.0M, was in Feb 2026.
Who leads Faeth Therapeutics?
Jayson Dallas is a Chief Executive Officer at Faeth Therapeutics.
What is the latest news on Faeth Therapeutics?
On Oct 27, 2026, Faeth Therapeutics Appoints Adam Schayowitz as Class III Director
Is Faeth Therapeutics a public company?
Yes. Faeth Therapeutics is publicly traded under the ticker FTH.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy